Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO for at least 3 months 2. Age ≥ 18 years 3. BMI ≥ 25.0 kg/m2 4. HbA1c ≥ 7.0 % 5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least 75 days  Prior or current use of any PPAR-γ agonist 2. Recent use (< 3 months) of an investigational drug 3. Pre-existing medical condition judged to preclude safe participation in the study 4. Contraindication/intolerance to study medication 5. Use of any drug which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids) 6. Diagnosed or receiving medication for heart failure, NYHA I to IV 7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV intervention 8. Uncontrolled treated/untreated systolic blood pressure >180 mmHg and/or diastolic blood pressure > 95 mmHg 9. Known diabetic macular oedema 10. Hematuria 11. Serum creatinine >130 μmol/l 12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of normal 13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L) below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c assay 14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods (adequate contraceptive measures are an intrauterine device or oral contraceptives) 15. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation 16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocols 17. Cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial